
TVG CEO discusses completion of recent projects
TVG CEO, Jeremy Salt, discusses the recent successful completion of the Streptococcus suis and transmissible Lassa fever vaccine projects.
TVG CEO, Jeremy Salt, discusses the recent successful completion of the Streptococcus suis and transmissible Lassa fever vaccine projects.
Most emerging infectious diseases affecting humans in the last century originated in animal reservoirs and are defined as zoonotic. Lassa fever is a significant zoonotic disease
TVG has completed a successful Anglo-Chinese project backed by the Department of Health and Social Care (DHSC), Innovate UK, and the Chinese Ministry of Science and
As TVG prepares for future growth a new position of Laboratory Manager has been created and we are delighted to announce that after an extensive recruitment
The Vaccine Group is proud to announce that Dr Michael Jarvis, TVG’s Chief Scientific Officer, has been recognised in the 2021 NIH Director’s Awards. Dr Jarvis
Trial data show strong T cell responses to SARS-CoV-2, as well as the more divergent SARS-CoV-1, demonstrating potential for broad immunity against current and future variants
The Vaccine Group (“TVG” or the “Company”) is pleased to announce the appointment of Dr Jeremy Salt as Chief Executive Officer. Jeremy has extensive experience in senior roles in
The Vaccine Group (“TVG” or the “Company”) today announces it is to collaborate with The Pirbright Institute (“Pirbright” or the “Institute”) to develop vaccine candidates to